Auxilium Testim Has 8.9% Share Of Testosterone Gel Scripts – IPO Prospectus
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is positioning Testim as offering a convenience and cost advantage over the only other gel product, Solvay's Androgel, and an efficacy advantage over Watson's Androderm testosterone patch.